BiotechTube
Home/Talisman Therapeutics/J. Mark Treherne
JM

J. Mark Treherne

Chairman of the Board

Talisman Therapeutics

Therapeutic Areas

Alzheimer's DiseaseNeurodegenerative Diseases

Talisman Therapeutics Pipeline

DrugIndicationPhase
Lysosome Biology ProgramNeurodegenerative DiseasesPreclinical
Pathogenic Protein Reduction ProgramNeurodegenerative Diseases (e.g., Alzheimer's)Preclinical
Microglial Health ProgramNeurodegenerative DiseasesPreclinical

Leadership Team at Talisman Therapeutics

RL
Rick Livesey
Chief Executive Officer
ES
Emily Scraggs
Commercial Director
JS
James Smith
Head of Scientific Operations
View full Talisman Therapeutics profile